Patient recruitment company, Medicollect, has decided to build and run proprietary patient panels within diabetes, COPD, and cardiovascular diseases.
Until now, the patient recruitment company has based its deliveries on existing patient panels from sub-contractors, but with the new strategy, it will be possible to provide more patients much faster and with a higher rate of randomization.
During spring 2014 Medicollect will establish The Diabetics Panel and shortly thereafter COPD and heart follows respectively.
Torben Lind, CEO in Medicollect, says: “Medicollect has tested several recruitment strategies, and we are confident that, with our new strategy, we have lined out a strong solution to the recruitment challenges faced by most global companies working with clinical trials.
We are truly looking forward to testing this solution in Denmark and then shortly after introducing it internationally”.
Want to know more?
Contact Torben Lind